Anti-IL-2 [NARA1]
Catalogue Number: AB03232-2.3-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | IL2; IL-2; TCGF; Interleukin-2; T-cell growth factor; Aldesleukin |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Mouse |
| Clone: | NARA1 |
| Isotype: | IgG2a |
| Immunogen: | The original antibody was generated immunizing Balb/c mice with human IL-2. |
| Application: | FC, InVitroA, InVivoA, SPR, Crstapy |
Additional Text
Gene Name
IL2
Gene ID
3558
Uniprot ID
P60568
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
SPR showed the binding of the antibody to IL-2 prevented further binding of hCD25 to IL-2; the affinity of the antibody to hIL-2 was ~10-9 M. The crystal structure of the Fab fragment in complex with IL-2 was determined. IL-2/antibody complexes preferentially expand CD8+ T and NK cells in vivo while disfavoring CD25+ Tregs in transplantable metastatic melanoma model. This difference was also confirmed by kinetic proliferation studies. The complex IL-2/antibody decreased the tumor growth in mice by increasing the CD8+ T cell responses. The IL-2/antibody complex immunotherapy was also efficacious in a spontaneous melanoma model in mice. The complex Il-2/antibody shows potential as a therapeutic agent as it achieved strong antitumor immune responses (Arenas-Ramirez et al., 2016; PMID: 27903862). In order to prevent in vivo dissociation of the complex IL-2/antibody, NARA1leukin was constructed by integrating IL-2 into the antigen-binding groove on the antibody. The NARA1leukin version showed a longer half-life in vivo and more expansion of CD8+ T and NK cells, with no association with CD25, leading to a stronger antitumor response in B16-F10 murine models (Sahin et al., 2020; PMID: 33353953). The use of hIL-2/NARA1 in combination with Ezh2, an inhibitor of the histone methyltransferase enhancer of zeste homolog 2, showed enhanced tumor control in several mouse models of melanoma (Zingg et al., 2017: PMID: 28746871).
AB03232-2.3-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations